User considers trying AAPE for hair restoration, costing $700 for 6 months. Others discuss its potential effectiveness and mention a study with promising results.
The conversation discusses the effectiveness of different versions of Pyrilutamide (KX-826) for hair loss, with skepticism about the cosmetic versions and interest in a new 1.0% version. Some users report success with products from Koshine, while others criticize Pyrilutamide's effectiveness compared to Minoxidil.
A user shared progress pictures after 40 days of using topical finasteride, minoxidil, and KX-826 following a hair transplant. They previously used Polaris NR-11, which contains finasteride and minoxidil, and experienced significant hair regrowth.
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
A 27-year-old male with androgenetic alopecia has been using finasteride, topical minoxidil, and microneedling for over six months to stabilize hair loss and prepare for a potential hair transplant. While some users suggest switching to dutasteride and increasing minoxidil usage, others note minimal progress, with some hair stabilization but concerns about thinning at the crown.
A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.
The user experienced significant hair darkening and progress in hair regrowth over six months using 5% topical minoxidil, 5 mg oral minoxidil, 1 mg finasteride, and weekly microneedling. No side effects were reported from these treatments.
The user is considering giving up on finasteride after 6 months due to lack of noticeable hair growth, but others suggest adding minoxidil and being patient as improvements can take longer. Many recommend continuing treatment and possibly adding minoxidil for better results.
The user has been using finasteride for 6.5 years and oral minoxidil for 10 months, experiencing slight regrowth on the temples but still has a thin crown. They are considering trying RU58841 and a derma stamp/pen for further treatment.
PP405 is criticized as ineffective compared to minoxidil and finasteride for treating hair loss. Users express skepticism about its potential, despite significant investment and claims of activating hair follicle stem cells.
A 25-year-old male has been using oral finasteride and minoxidil for six months without noticeable progress in hair regrowth and is considering switching to dutasteride or a hair transplant. Users suggest giving the treatment more time, adding microneedling, and possibly using topical minoxidil.
After six months on 1.25 mg of finasteride, a user reports significant hair regrowth with no major shedding and uses a local brand of the medication. Some users inquire about side effects and brand differences, while others share their own experiences and concerns about hair loss treatment.
People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.
A user's progress with hair loss treatments such as derma pen, minoxidil/finasteride topical, RU58841, oils and Hims shampoo over 6 months. The replies are full of encouragement for continued progress.
, you can find it online with a script
This user was discussing their progress with hair loss treatments including 5mg oral Minoxidil and combining 3mg oral Minoxidil with MTF HRT. They also discussed side effects of increased body hair in other parts of the body.
User reports 7 months progress using Finasteride, Minoxidil, and Keto Shampoo & Conditioner, with positive results and no side effects. Others in the conversation congratulate the user and discuss the effectiveness of the treatments.
The user tried finasteride for 6 months without noticeable improvement and is considering switching to dutasteride. They also used ketoconazole shampoo a few times a week.
The conversation discusses hair loss treatments, specifically the use of finasteride (Fin) and oral minoxidil (Oral Min), with progress shown using hair fibers like DermMatch and Toppik. The original poster plans a hair transplant and mentions side effects like reduced libido from finasteride.
The conversation discusses a community called PHG, which focuses on experimental hair loss treatments and scientific approaches to hair regrowth. It mentions treatments like Minoxidil, finasteride, and RU58841, and highlights interest in new treatments like Setipripant, Histogen, and Replicel.
The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.
The conversation discusses hair loss treatment using finasteride, minoxidil chews, 0.5 dermarolling, 2% ketoconazole, and a silk bonnet. The user reports positive progress and plans to continue the regimen.
The user is using finasteride, HGH, GHK-CU, BPC-157, KPV, biotin/collagen/keratin vitamins, ketoconazole shampoo, and low-dose naltrexone to address hair loss, avoiding minoxidil due to past shedding experiences. Adenosine is discussed as a potential alternative to minoxidil, though it is noted to be expensive and hard to find.
The conversation discusses a product called Rexagain Mixprocapil, which includes topical finasteride. Users express skepticism about the product's legitimacy and caution about its use.
The user tried various hair loss treatments, including finasteride, minoxidil, dutasteride, and a hair transplant, but experienced continued hair thinning. Stress, genetics, and past medication use are considered possible factors.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.